At Aptar Digital Health, we strongly believe that combining a prescription drug (Rx) with digital therapeutics (DTx) — or what we call “Digitally Augmented Therapies” — can improve the treatment value, leading to better treatment adherence for patients living with chronic conditions or receiving specific medicine. According to EvaluatePharma1, total prescription drug sales are expected to grow from $904Bn in 2020 to $1.4T by 2026. During the same period, $252Bn is considered at risk due to patent expiry. Rx/DTx combinations support a drug asset throughout its lifecycle, from day one on the market to the start of its decline due to the entry of generics and more competitive alternatives.
“*” indicates required fields